BRAIN and NERVE－神経研究の進歩71巻6号

2019年06月発行

特集 補体標的治療の現状と展望

視神経脊髄炎

著者： 黒田宙¹ 藤原一男²

所属機関： ¹東北大学医学部神経内科 ²福島県立医科大学医学部多発性硬化症治療学

ページ範囲：P.573 - P.580

文献概要

自己抗体が病態に関わる神経疾患に対し，従来は主にリンパ球および抗体を標的とする治療が行われてきた。近年，これらの疾患群の中に自己抗体のみならず補体活性化が組織傷害発現に深く関わる疾患が複数存在することが明らかにされ，補体標的治療の臨床応用が始まっている。本稿では視神経脊髄炎について，疾患病態への補体関与と補体標的治療の現況について近年の進歩を踏まえて概説する。

参考文献

1)Fujihara K, Misu T, Nakashima I, Takahashi T, Bradl M, et al: Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3: 58-73, 2012

2)Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG: The spectrum of neuromyelitis optica. Lancet Neurol 6: 805-815, 2007

3)Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004

4)Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477, 2005

5)Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, et al: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85: 177-189, 2015

6)Verkman AS, Ratelade J, Rossi A, Zhang H, Tradtrantip L: Aquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica. Acta Pharmacol Sin 32: 702-710, 2011

7)Neely JD, Christensen BM, Nielsen S, Agre P: Heterotetrameric composition of aquaporin-4 water channels. Biochemistry 38: 11156-11163, 1999

8)Furman CS, Gorelick-Feldman DA, Davidson KG, Yasumura T, Neely JD, et al: Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. Proc Natl Acad Sci U S A 100: 13609-13614, 2003

9)Rash JE, Davidson KG, Yasumura T, Furman CS: Freeze-fracture and immunogold analysis of aquaporin-4 (AQP4) square arrays, with models of AQP4 lattice assembly. Neuroscience 129: 915-934, 2004

10)Crane JM, Verkman AS: Determinants of aquaporin-4 assembly in orthogonal arrays revealed by live-cell single-molecule fluorescence imaging. J Cell Sci 122: 813-821, 2009

11)Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, et al: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63: 964-968, 2006

12)Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, et al: Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224-1234, 2007

13)Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, et al: Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66: 630-643, 2009

14)Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, et al: Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 66: 1164-1167, 2009

15)Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, et al: Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 386: 623-627, 2009

16)Herwerth M, Kalluri SR, Srivastava R, Kleele T, Kenet S, et al: In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Ann Neurol 79: 794-805, 2016

17)Takano R, Misu T, Takahashi T, Sato S, Fujihara K, et al: Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75: 208-216, 2010

18)Kuroda H, Fujihara K, Takano R, Takai Y, Takahashi T, et al: Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 254: 178-182, 2013

19)Kinoshita M, Nakatsuji Y, Moriya M, Okuno T, Kumanogoh A, et al: Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 20: 508-512, 2009

20)Nishiyama S, Misu T, Nuriya M, Takano R, Takahashi T, et al: Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: pathogenetic implications in neuromyelitis optica. Biochem Biophys Rep 7: 45-51, 2016

21)Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, et al: Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69: 2221-2231, 2007

22)Burton DR, Boyd J, Brampton AD, Easterbrook-Smith SB, Emanuel EJ, et al: The Clq receptor site on immunoglobulin G. Nature 288: 338-344, 1980

23)Matiello M, Schaefer-Klein J, Sun D, Weinshenker BG: Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 70: 1118-1125, 2013

24)Tüzün E, Kürtüncü M, Türkoğlu R, Içöz S, Pehlivan M, et al: Enhanced complement consumption in neuromyelitis optica and Behçet's disease patients. J Neuroimmunol 233: 211-215, 2011

25)Chen Y, Li R, Wu AM, Shu YQ, Lu ZQ, et al: The complement and immunoglobulin levels in NMO patients. Neurol Sci 35: 215-220, 2014

26)Nytrova P, Potlukova E, Kemlink D, Woodhall M, Horakova D, et al: Complement activation in patients with neuromyelitis optica. J Neuroimmunol 274: 185-191, 2014

27)Veszeli N, Füst G, Csuka D, Trauninger A, Bors L, et al: A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Mol Immunol 57: 200-209, 2014

28)Wang H, Wang K, Wang C, Qiu W, Lu Z, et al: Increased soluble C5b-9 in CSF of neuromyelitis optica. Scand J Immunol 79: 127-130, 2014

29)Verkman AS, Anderson MO, Papadopoulos MC: Aquaporins: important but elusive drug targets. Nat Rev Drug Discov 13: 259-277, 2014

30)Suzuki N, Takahashi T, Aoki M, Misu T, Konohana S, et al: Neuromyelitis optica preceded by hyperCKemia episode. Neurology 74: 1543-1545, 2010

31)Guo Y, Lennon VA, Popescu BF, Grouse CK, Topel J, et al: Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol 71: 1025-1029, 2014

32)Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, et al: Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology 86: 79-87, 2016

33)Saadoun S, Waters P, Leite MI, Bennett JL, Vincent A, et al: Neuromyelitis optica IgG causes placental inflammation and fetal death. J Immunol 191: 2999-3005, 2013

34)Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, et al: Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71: 314-322, 2012

35)Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, et al: C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 52: 91-112, 2000

36)Donaldson VH, Evans RR: A biochemical abnormality in herediatry angioneurotic ddema: absence of serum inhibitor of C' 1-esterase. Am J Med 35: 37-44, 1963

37)Fattouch K, Bianco G, Speziale G, Sampognaro R, Lavalle C, et al: Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwent surgical reperfusion: a randomised double-blind study. Eur J Cardiothorac Surg 32: 326-332, 2007

38)Igonin AA, Protsenko DN, Galstyan GM, Vlasenko AV, Khachatryan NN, et al: C1-esterase inhibitor infusion increases survival rates for patients with sepsis*. Crit Care Med 40: 770-777, 2012

39)Levy M, Mealy MA: Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 1: e5, 2014［doi: 10.1212/NXI.0000000000000005］

40)Phuan PW, Zhang H, Asavapanumas N, Leviten M, Rosenthal A, et al: C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol 125: 829-840, 2013

41)Kim JS, Cheon S, Kim SW, Kim B, Kim H, et al: Glycyrrhizic acid prevents astrocyte death by neuromyelitis optica-specific IgG via inhibition of C1q binding. Biochem Biophys Res Commun 478: 553-558, 2016

42)Miyata T, Yamada N, Iida Y, Nishimura J, Takeda J, et al: Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 330: 249-255, 1994

43)Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, et al: Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350: 552-559, 2004

44)Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, et al: Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368: 2169-2181, 2013

45)Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, et al: Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16: 976-986, 2017

46)Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, et al: Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12: 554-562, 2013

47)U.S. National Library of Medicine: A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study). https://clinicaltrials.gov/ct2/show/NCT01892345.（最終閲覧日2019年3月12日）

48)Alexion Announces Successful Phase 3 PREVENT Study Of Soliris® (Eculizumab) In Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD). https://news.alexionpharma.com/press-release/product-news/alexion-announces-successful-phase-3-prevent-study-soliris-eculizumab-pat（最終閲覧日2019年3月12日）